Amazon has decided to suspend nonessential item shipments; study results show patients with chronic obstructive pulmonary disease (COPD) benefited from a fluticasone furoate/umeclidinium/vilanterol combination inhaler; disruptions from the coronavirus now extend to proposed mergers among industry giants.
Beginning yesterday, Amazon decided to suspend shipments of nonessential items to US and UK warehouses, reports The Hill, through at least April 5. This change in operations was triggered by the coronavirus pandemic, which itself triggered a jump in online shopping with social distancing and remote working the norm for the forseeable future. Shopping habits have also changed, with there now being a greater call for medical supplies and household staples.
Study results published recently in the American Journal of Respiratory and Critical Care Medicine show that using a combination inhaler of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) just once a day to treat chronic obstructive pulmonary disease (COPD) could reduce all-cause mortality by 42%. Trial participants also exhibited improved lung function and health-related quality of life. Followed for 1 year, they were randomized to 1 of 3 combination groups: FF/UMEC/VI, FF/VI, or UMEC/VI. According to the study authors, “No previous study has prospectively demonstrated that drug therapy can reduce all-cause mortality in people with COPD. Major studies done prior to IMPACT suggested mortality reductions, but were not able to prove this with certainty.”
Google and FitBit, along with AbbVie and Allergan, have witnessed their planned mergers be stymied by the worldwide coronavirus crisis, according to Bloomberg. Officials from the Department of Justice and Federal Trade Commission say their agencies need extra time to gather the necessary documents and conduct antitrust investigations, both of which have been hampered by the pandemic. AbbVie is planning to shell out $63 billion for Allergan, while Google will spend $2.1 billion for FitBit. Antitrust investigations can often last 1 or more years.
Dose-Escalation, Low-Dose Regimens May Improve Roflumilast Treatment Adherence in Patients With COPD
March 24th 2024This study suggests that dose-escalation or low-dose regimens for roflumilast treatment in patients with chronic obstructive pulmonary disease (COPD) may improve adherence.
Read More
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
Similar In-Hospital, Long-Term Survival Rates Found Among Male, Female Patients With AECOPD
March 18th 2024This study analyzed sex differences among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), with findings indicating that female smokers experience worse hospital outcomes despite similar overall survival rates.
Read More
Frailty, Depression Can Affect Social Support, Self-Management in Older Patients With COPD
March 8th 2024Self-management (SM) among older patients with chronic obstructive pulmonary disease (COPD) is moderately low, and frailty and depression may partially mediate the relationship between social support and SM in these patients.
Read More